Table of Content

Open Access iconOpen Access

ARTICLE

Targeting CD47 Enhances the Efficacy of Anti-PD-1 and CTLA-4 in an Esophageal Squamous Cell Cancer Preclinical Model

Hua Tao, Pudong Qian, Feijiang Wang, Hongliang Yu, Yesong Guo

Radiotherapy Oncology Department, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu, P.R. China

Oncology Research 2017, 25(9), 1579-1587. https://doi.org/10.3727/096504017X14900505020895

Abstract

Esophageal squamous cell cancer is a highly aggressive cancer with a dismal 5-year survival rate. CD47 is a cell transmembrane protein that is involved in cell apoptosis, proliferation, adhesion, migration, and antigen presentation in the immune system. By interacting with signal regulatory protein-a expressed in antigenpresenting cells (APCs), CD47 acts as an antiphagocytic mechanism to inhibit APC-dependent antigen presentation. Overexpression of CD47 was found in various types of cancer. However, its role in esophageal squamous cell cancer is not yet clear. Anti-CD47 is an antagonist of CD47 signaling pathways by competing with its ligand. In the current study, we investigated the effects of anti-CD47 treatment on the antitumor immune response in an esophageal squamous cell cancer preclinical model. We found that anti-CD47 treatment enhanced proinflammatory responses and increased CD8+ T-cell infiltration in tumor tissue in the animal model. T cells in anti-CD47-treated tumors showed higher PD-1 and CTLA-4 expression, indicating T-cell activation and the rationale of combining anti-CD47 with anti-PD-1 and CLTA-4. The combinatory treatment showed the best antitumor response, implying a novel treatment strategy. The effects of anti-CD47 depended on dendritic cell function. In patient samples, expression of CD47 was negatively correlated with CD8+ T-cell infiltration in esophageal squamous cell cancer patients. Taken together, CD47 might be a novel target to enhance anti-PD-1 and CLTA-4 efficacy in esophageal squamous cell cancer.

Keywords


Cite This Article

APA Style
Tao, H., Qian, P., Wang, F., Yu, H., Guo, Y. (2017). Targeting CD47 enhances the efficacy of anti-pd-1 and CTLA-4 in an esophageal squamous cell cancer preclinical model. Oncology Research, 25(9), 1579-1587. https://doi.org/10.3727/096504017X14900505020895
Vancouver Style
Tao H, Qian P, Wang F, Yu H, Guo Y. Targeting CD47 enhances the efficacy of anti-pd-1 and CTLA-4 in an esophageal squamous cell cancer preclinical model. Oncol Res. 2017;25(9):1579-1587 https://doi.org/10.3727/096504017X14900505020895
IEEE Style
H. Tao, P. Qian, F. Wang, H. Yu, and Y. Guo "Targeting CD47 Enhances the Efficacy of Anti-PD-1 and CTLA-4 in an Esophageal Squamous Cell Cancer Preclinical Model," Oncol. Res., vol. 25, no. 9, pp. 1579-1587. 2017. https://doi.org/10.3727/096504017X14900505020895



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 37

    View

  • 23

    Download

  • 0

    Like

Share Link